S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
"Prepare for Five Years of Famine" (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The Market Crash Shield is A.I. (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
"Prepare for Five Years of Famine" (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The Market Crash Shield is A.I. (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
"Prepare for Five Years of Famine" (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The Market Crash Shield is A.I. (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
Mullen Automotive Makes Deliveries; Short-Squeeze Possible
"Prepare for Five Years of Famine" (Ad)
Schwab’s Drop This Week Could Be The Opening Of The Year (Again)
What is a Gold IRA, and is it a Viable Investment?
"Prepare for Five Years of Famine" (Ad)
Closing prices for crude oil, gold and other commodities
Walmart Shares Jump on Evercore Analyst Upgrade 
The Market Crash Shield is A.I. (Ad)pixel
Is Braze, Inc Ready To Rocket Higher? 
Can Frontline Maintain This Momentum?
NASDAQ:TLRY

Tilray - TLRY Stock Forecast, Price & News

$2.53
+0.01 (+0.40%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.52
$2.59
50-Day Range
$2.36
$3.35
52-Week Range
$2.28
$9.08
Volume
6.49 million shs
Average Volume
11.66 million shs
Market Capitalization
$1.56 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.72

Tilray MarketRank™ Forecast

Analyst Rating
Hold
1.75 Rating Score
Upside/​Downside
86.5% Upside
$4.72 Price Target
Short Interest
Bearish
9.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.33) to ($0.14) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Consumer Staples Sector

118th out of 136 stocks

Medicinals & Botanicals Industry

8th out of 10 stocks


TLRY stock logo

About Tilray (NASDAQ:TLRY) Stock

Tilray Inc is a pharmaceutical and cannabis company founded in 2013 and headquartered in Nanaimo, Canada. The company operates in the United States, Europe, Canada, Australia and Latin America. Tilray is known for producing and distributing medical and recreational cannabis products.

Tilray Inc is primarily engaged in the production, research, development and distribution of medical and recreational cannabis products. The company's product portfolio includes dried cannabis, cannabis oil and capsules. Tilray also produces and distributes hemp-based food products, such as hemp hearts and hemp protein powder.

Tilray operates in two segments: Cannabis and Hemp. The Cannabis segment includes medical and adult-use cannabis, and the Hemp segment includes hemp food products and hemp-based CBD products.

The company's stock price has fluctuated significantly over the past few years. Tilray Inc accredits these fluctuations to changing legal landscapes, changing demands of its clients and increasing competition.

Tilray Inc faces significant competition in the cannabis and hemp industries. The company competes with other cannabis producers, such as Canopy Growth Corporation and Aurora Cannabis Inc, as well as with companies that produce hemp-based products, such as Hemp Inc and Charlotte's Web Holdings Inc.

Tilray also faces competition from illegal cannabis producers, particularly in countries where cannabis is still illegal. The company's success will depend on its ability to compete effectively in the legal cannabis and hemp markets and to expand into new markets as legalization continues.

Tilray Inc's growth prospects are closely tied to legalizing cannabis and hemp products. The company has already expanded its operations into several countries where cannabis is legal, such as Canada, the United States and Germany.

Tilray's merger with Aphria Inc in May 2021 has also given the company multiple growth opportunities. The merger created the world's largest cannabis company, with a market capitalization of over $5 billion. The combined company has a strong presence in Canada, Europe and the United States and is well-positioned to benefit from the continued legalization of cannabis and hemp products.

The company's focus on research and development also provides significant growth opportunities. Tilray has a research and development facility in Canada, conducting clinical trials to evaluate the effectiveness of cannabis and hemp-based products for medical purposes.

Tilray Inc faces several risks and challenges, particularly in the current regulatory environment. Cannabis and hemp products are still illegal in many countries, which limits the company's growth opportunities. Even in countries where cannabis is legal, the regulatory environment can be complex and rapidly evolving, creating challenges for the company's operations.

Tilray's success also depends on its ability to compete effectively in a crowded market. The company faces competition from other cannabis and hemp producers, as well as from illegal producers. The company's success will depend on its ability to differentiate itself from its competitors and build a strong brand that resonates with consumers.

Receive TLRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tilray and its competitors with MarketBeat's FREE daily newsletter.

TLRY Stock News Headlines

Should You Buy Tilray Brands (TLRY) Ahead of Earnings?
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Where Will Tilray Brands Be in 5 Years?
2 Reasons to Sell Tilray Stock and 1 Reason to Buy It
Sell every Stock except ONE
Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...
Unusual Put Option Trade in Tilray Worth $132.27K
Good Supply Cannabis Brand Launches New Product Lineup
Why Tilray (TLRY) Shares Are Falling
Stifel Nicolaus Reaffirms Their Hold Rating on Tilray (TLRY)
1 Thing Tilray Investors Need to Brace for This Year
Why Is Tilray Stock So Cheap?
Here's How Tilray Could Grow by 3X Before 2027
See More Headlines
Receive TLRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tilray and its competitors with MarketBeat's FREE daily newsletter.

TLRY Company Calendar

Last Earnings
1/09/2023
Today
3/31/2023
Next Earnings (Confirmed)
4/10/2023
Fiscal Year End
5/31/2023

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Current Symbol
NASDAQ:TLRY
Fax
N/A
Employees
1,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.72
High Stock Price Forecast
$9.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+86.5%
Consensus Rating
Hold
Rating Score (0-4)
1.75
Research Coverage
8 Analysts

Profitability

Net Income
$-476,800,000.00
Pretax Margin
-90.10%

Debt

Sales & Book Value

Annual Sales
$628.37 million
Book Value
$8.34 per share

Miscellaneous

Free Float
599,861,000
Market Cap
$1.56 billion
Optionable
Optionable
Beta
2.70

Key Executives

  • Mr. Edward Wood Pastorius Jr. (Age 50)
    Chief Revenue Officer
  • Mr. Brendan  KennedyMr. Brendan Kennedy (Age 46)
    Pres, CEO & Director
  • Mr. Mark Castaneda (Age 53)
    CFO, Sec. & Treasurer
  • Dr. Catherine Jacobson
    Director of Clinical Research & Member of Medical Advisory Board













TLRY Stock - Frequently Asked Questions

Should I buy or sell Tilray stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tilray in the last twelve months. There are currently 2 sell ratings and 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TLRY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TLRY, but not buy additional shares or sell existing shares.
View TLRY analyst ratings
or view top-rated stocks.

What is Tilray's stock price forecast for 2023?

8 Wall Street research analysts have issued 12-month price targets for Tilray's stock. Their TLRY share price forecasts range from $2.00 to $9.00. On average, they expect the company's share price to reach $4.72 in the next twelve months. This suggests a possible upside of 86.5% from the stock's current price.
View analysts price targets for TLRY
or view top-rated stocks among Wall Street analysts.

How have TLRY shares performed in 2023?

Tilray's stock was trading at $2.69 on January 1st, 2023. Since then, TLRY shares have decreased by 5.9% and is now trading at $2.53.
View the best growth stocks for 2023 here
.

When is Tilray's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, April 10th 2023.
View our TLRY earnings forecast
.

How can I listen to Tilray's earnings call?

Tilray will be holding an earnings conference call on Monday, April 10th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Tilray's earnings last quarter?

Tilray Inc (NASDAQ:TLRY) issued its quarterly earnings data on Monday, January, 9th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.01. The company had revenue of $144.10 million for the quarter, compared to analysts' expectations of $157.21 million. Tilray had a negative trailing twelve-month return on equity of 5.10% and a negative net margin of 89.96%. The business's revenue was down 7.1% on a year-over-year basis.

What is Brendan Kennedy's approval rating as Tilray's CEO?

32 employees have rated Tilray Chief Executive Officer Brendan Kennedy on Glassdoor.com. Brendan Kennedy has an approval rating of 51% among the company's employees. This puts Brendan Kennedy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tilray own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tilray investors own include Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Block (SQ).

When did Tilray IPO?

(TLRY) raised $135 million in an initial public offering on Thursday, July 19th 2018. The company issued 9,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Company served as the underwriter for the IPO and Roth Capital Partners and Northland Securities were co-managers.

What is Tilray's stock symbol?

Tilray trades on the NASDAQ under the ticker symbol "TLRY."

Who are Tilray's major shareholders?

Tilray's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Susquehanna International Group LLP (0.00%), Marshall Wace LLP (0.40%), Mirae Asset Global Investments Co. Ltd. (0.39%), Millennium Management LLC (0.38%), Sculptor Capital LP (0.00%) and Swiss National Bank (0.21%). Insiders that own company stock include Brendan Kennedy, Carl A Merton, Christine StClare, James R Meiers, Maryscott Greenwood and Michael Auerbach.
View institutional ownership trends
.

How do I buy shares of Tilray?

Shares of TLRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tilray's stock price today?

One share of TLRY stock can currently be purchased for approximately $2.53.

How much money does Tilray make?

Tilray (NASDAQ:TLRY) has a market capitalization of $1.56 billion and generates $628.37 million in revenue each year. The company earns $-476,800,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis.

How many employees does Tilray have?

The company employs 1,800 workers across the globe.

How can I contact Tilray?

Tilray's mailing address is 1100 MAUGHAN ROAD, NANAIMO A1, V9X 1J2. The official website for the company is www.tilray.com. The company can be reached via phone at 206-432-9325.

This page (NASDAQ:TLRY) was last updated on 4/1/2023 by MarketBeat.com Staff